Revolutionary AI-powered blood test for cancer enters NHS trials
Baku, April 25, AZERTAC
A groundbreaking blood test that uses artificial intelligence to detect cancer from just a few drops of blood is entering clinical trials across the UK’s National Health Service (NHS), according to Kazinform.
The test, called miONCO-Dx, has the potential to revolutionize cancer detection, offering a fast, non-invasive method for identifying up to 12 of the most common and deadly cancers — including bowel, breast, lung, ovarian, and pancreatic — with over 99% accuracy.
Cancer remains a leading global health threat, particularly in the United States, where it is the second leading cause of death, claiming more than 600,000 lives annually. Early detection significantly improves survival rates. For instance, nine in ten bowel cancer patients survive if diagnosed at stage one, but this number drops to just one in ten when detected at stage four.
The upcoming NHS clinical trial will involve 8,000 patients, building on earlier data collected from over 20,000 individuals. The project has received £2.4 million in government funding and is considered a potential game-changer for cancer diagnosis, especially as healthcare systems face mounting pressure.
Other news in this section
